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correlation between SHP-2 activity and PD-L1
expression and suggests synergy in
combining SHP-2 and PD-1/PD-L1 inhibitors
Keller J. Toral, Mark A. Wuenschel, Esther P. BlackID*
Department of Pharmaceutical Sciences and Markey Cancer Center, College of Pharmacy, University of
Kentucky, Lexington, Kentucky, United States of America
* penni.black@uky.edu
Abstract
The identification of novel therapies, new strategies for combination of therapies, and repur-
posing of drugs approved for other indications are all important for continued progress in the
fight against lung cancers. Antibodies that target immune checkpoints can unmask an
immunologically hot tumor from the immune system of a patient. However, despite accounts
of significant tumor regression resulting from these medications, most patients do not
respond. In this study, we sought to use protein expression and RNA sequencing data from
The Cancer Genome Atlas and two smaller studies deposited onto the Gene Expression
Omnibus (GEO) to advance our hypothesis that inhibition of SHP-2, a tyrosine phospha-
tase, will improve the activity of immune checkpoint inhibitors (ICI) that target PD-1 or PD-
L1 in lung cancers. We first collected protein expression data from The Cancer Proteome
Atlas (TCPA) to study the association of SHP-2 and PD-L1 expression in lung adenocarci-
nomas. RNA sequencing data was collected from the same subjects through the NCI
Genetic Data Commons and evaluated for expression of the PTPN11 (SHP-2) and CD274
(PD-L1) genes. We then analyzed RNA sequencing data from a series of melanoma
patients who were either treatment naïve or resistant to ICI therapy. PTPN11 and CD274
expression was compared between groups. Finally, we analyzed gene expression and drug
response data collected from 21 non-small cell lung cancer (NSCLC) patients for PTPN11
and CD274 expression. From the three studies, we hypothesize that the activity of SHP-2,
rather than the expression, likely controls the expression of PD-L1 as only a weak relation-
ship between PTPN11 and CD274 expression in either lung adenocarcinomas or melano-
mas was observed. Lastly, the expression of CD274, not PTPN11, correlates with response
to ICI in NSCLC.
Introduction
Lung cancers remain a leading cause of cancer morbidity and mortality worldwide despite
increased efforts toward drug discovery and implementation of personalized medicine
PLOS ONE
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approaches [1]. Perhaps the most significant advance in therapy for many cancer types was the
entry of immune checkpoint inhibitors (ICI) as a standard of care therapy for melanomas in
2014 [2]. For non-small cell lung cancers (NSCLC), specifically those without targetable muta-
tions in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK),
immune checkpoint inhibitors, specifically the antibodies that target programmed cell death 1
(PD-1) or programmed death ligand 1 (PD-L1), have revolutionized cancer therapy even
though response rates are relatively low [3]. Both pembrolizumab and atezolizumab are
approved ICI for frontline lung adenocarcinoma therapy for patients with high levels of PD-L1
expression on tumor cells [4]. Durvalumab, an anti-PD-1 agent, is approved as maintenance
therapy [5]. Decisions to implement ICI therapy is often dependent on the PD-L1 tumor pro-
portion score using evidence from the KEYNOTE-024 and -042 trials [6, 7]. Importantly,
PD-L1 expression may not be the optimal biomarker of response as suggested in pivotal clini-
cal studies (e.g. KEYNOTE and OAK), but it is clear that patients with high levels of tumoral
PD-L1 are likely to experience a robust response to checkpoint inhibition [8]. While many
research groups have searched for improved biomarkers of response for checkpoint inhibitors,
others have focused on identification of therapies that might be combined with ICI to improve
patient outcomes. The work presented herein falls into the latter category [9].
Our group found that inhibition of the tyrosine phosphatase, SHP-2, increased gene and
cell surface protein expression of PD-L1 in KRAS-active NSCLC cell lines (manuscript submit-
ted). PD-L1 is normally expressed on the surface of antigen presenting cells while PD-1 is
expressed on T cells. It is the abnormal expression of PD-L1 on tumor cells, and the subse-
quent engagement with PD-1 on T cells, that causes tumors to be masked from an immune
response [10]. Inhibiting this interaction with antibodies against either PD-1 or PD-L1 can
release a potent immune response toward the tumor.
We hypothesized that because SHP-2 provides some control of expression of PD-L1 on
NSCLC cells that inhibition of SHP-2 would increase PD-L1 expression and synergize with
ICI therapy. Supportive of our hypothesis is recently published data by Chen and colleagues
showed in a NSCLC model system that combined SHP2 and PD-L1 inhibition, with accompa-
nying radiation, can overcome resistance to PD-1 inhibitors [11]. Other groups have suggested
that SHP-2 activity may be more important in T cells, that infiltrate the tumor, to carry out sig-
naling events downstream of PD-1 stimulation [12]. Uncovering the precise mechanism of
SHP-2 action on PD-L1 expression consumes many research groups, the model systems are
expensive, and experimental time is long to get a drug to the clinic. In this study, we chose to
go straight to real world data to determine whether SHP-2 activity is related to PD-L1 expres-
sion and thereby focus our research efforts.
We took advantage of three publicly-available data sets to assess whether moving forward
with wet lab experimentation to determine if exploring the combination of ICI and SHP-2
inhibition is warranted. First, The Cancer Genome Atlas, now known as the NCI Genetic Data
Portal (NCI-GDC), holds well-annotated expression and functional proteomic data (The Can-
cer Proteome Atlas (TCPA)) for patient tumors. However, most samples were collected prior
to FDA approvals for ICI therapy, so no response data for ICI treatment is available (https://
portal.gdc.cancer.gov/projects/TCGA-LUAD). Unfortunately, larger, industry-sponsored tri-
als are still open (e.g. KEYNOTE and OAK), and full genomic and patient response datasets
are not yet published. Therefore, in order to link expression of SHP-2 and PD-L1 with
response to ICI, we uncovered two small studies: one in NSCLC and one in melanoma patients
[13, 14]. Using real world data from the three studies identified, we believe that inhibition of
SHP-2 activity is likely to improve response to PD-L1/PD-1 inhibitors and justifies continue
wet-lab characterization of the mechanism(s) of activity.
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GDC. Specifically, 1) for NCI-GDC, we used the
"TCGA-LUAD" data set (similarly, the TCPA used
the TCGA-LUAD-L4 subset); 2) for PMID:
30388455, GEO accession# GSE115978; 3) for
PMID: 31959763, GEO accession# GSE136961;
and 4) for PMID: 32015526, we used the full
dataset.
Funding: The authors received no specific funding
for this study.
Competing interests: The authors have declared
that no competing interests exist.
Methods and results
Phosphorylated SHP-2 significantly correlates with the loss of PD-L1
expression in lung adenocarcinomas
First, using TCPA (https://tcpaportal.org/tcpa/index.html), a functional proteomics database
which contains reverse phase protein array (RPPA) data from a wide variety of clinical tumor
samples, we identified a lung adenocarcinoma (TCGA-LUAD-L4) dataset containing RPPA
data from 362 individual patient samples. These data contain quantitative protein expression
levels of 237 unique proteins for each subject.
From the TCPA data, SHP-2_ pY542, the phosphorylated and active form of SHP-2, and
PD-L1 were compared from 362 patient tumors for relative protein expression levels using a
two-tailed, non-parametric Spearman correlation analysis with 95% confidence intervals. The
analysis revealed that levels of SHP-2_pY542 negatively correlate with PD-L1 expression (r =
-0.157, p-value = 0.0028��) in these subjects, suggesting that inhibition of SHP-2 activity may
increase PD-L1 protein expression (Figs 1A and 2A). Data capture and analysis was auto-
mated, and the annotated code in Python is linked here: (https://github.com/mwu228/
Summer2021/blob/main/Correlate%20proteins%20of%20interest.ipynb).
The data contained in the TCPA contained only expression levels of the active, phosphory-
lated SHP-2, so we were unable to compare interactions with the unphosphorylated form.
Thus, we looked to proteins in the TCPA dataset known to be in signaling cascades controlled
by SHP-2 activity as internal controls, specifically Src, STAT3, and MAPK (need references
here). We conducted the same correlation analysis between SHP-2_pY542 and either
Src_pY527, Src_pY416, STAT3_pY705, or MAPK_pT202Y204. We found that the levels of
active SHP-2 maintain strong (r> 0.4) and statistically significant (p< 1x10-15) positive corre-
lations with each of these four proteins, providing additional support that the Y542 phosphor-
ylation of SHP-2 correlation with PD-L1 protein expression is a meaningful interaction
(S1 Fig).
Next, to better understand the relationship between expression of SHP-2 (PTPN11) and
PD-L1 (CD274) mRNA in these patient tumors, we acquired corresponding RNA-sequencing
data from TCGA, now known as the NCI-GDC (https://portal.gdc.cancer.gov). In this data-
base, the TCGA-LUAD dataset contained 585 tumor samples, 223 more than the TCPA data.
To look at only RNA-sequencing data that matched the previously-queried RPPA data, the
362 patient identifiers provided by the TCPA database were used to identify the corresponding
RNA-sequencing data deposited into the GDC. We utilized fragments per kilobase-upper
quartile (FPKM-UQ) values. The FKPM-UQ values for the genes PTPN11 and CD274 for
each tumor were subjected to the same Spearman correlation analysis as previously described.
Data capture and analysis was automated, and the annotated code in Python is linked here:
(https://github.com/mwu228/Summer2021/blob/main/RNAseq%20FPKM%20correlation%
20and%20pvalue.ipynb).
Interestingly, this analysis revealed no significant correlation (p-value = 0.3488) between
PTPN11 and CD274 mRNA expression levels (Fig 1B). Following this observation, we wanted
to know if any relationship between PTPN11 and CD274 expression was found using the
entire TCGA-LUAD RNA-sequencing dataset (n = 585). We found a slight positive correlation
existed (r = 0.095, p-value = 0.0211�) between PTPN11 and CD274 mRNA levels (Fig 1C).
Because we are most interested in the role of SHP-2 in KRAS-active LUAD, we sub-grouped
tumors with variants of KRAS known to be active from this dataset. No significant relationship
was found in KRAS-active lung adenocarcinomas between PTPN11 and CD274 levels (S2 Fig).
Extending our observations from the aforementioned data that suggest a relationship
between SHP-2 activity and PD-L1 expression, we identified another data warehouse
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(cBioPortal: cbioportal.org) that contains gene expression data from clinical cancer studies.
Specifically, we located a study sought to characterize the genomic landscape of lung adenocar-
cinomas in East Asians [15]. This study contains RNAseq data for 169 patients, from which we
conducted a two-tailed, non-parametric Spearman correlation analysis with 95% confidence
intervals between PTPN11 and CD274 mRNA levels (normalization method: z-score). The
analysis revealed a positive (r = 0.267) and significant (p-value = 0.0005���) correlation
Fig 1. SHP-2 activity and expression correlates with expression of PD-L1 in NSCLC adenocarcinomas. A. Two-tailed non-parametric Spearman
correlation analysis of RPPA protein expression data for Y542 phosphorylated SHP-2 and PD-L1 from 362 adenocarcinomas taken from The Cancer
Proteome Atlas (TCPA: https://gdc.cancer.gov/about-data/publications/pancanatlas) LUAD-L4 dataset. B. Two-tailed non-parametric Spearman
correlation analysis of bulk RNA-seq FPKM-UQ values taken from TCGA (GDC) for the 362 patients that had corresponding RPPA protein
expression data from TCPA. C. Two-tailed non-parametric Spearman correlation analysis of bulk RNA-seq FPKM-UQ values taken from TCGA
(GDC) for all 585 patients in the TCGA-LUAD dataset. D. Two-tailed non-parametric Spearman correlation analysis of mRNA z-scores taken from
cBioPortal (PMID:32015526) for 169 lung adenocarcinoma tumors. The red line in each panel represents a linear regression line of best fit.
https://doi.org/10.1371/journal.pone.0256416.g001
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between PTPN11 and CD274 mRNA, again suggesting that SHP-2 and PD-L1 protein are co-
expressed in LUAD tumors (Fig 1D). Together, these TCPA and RNA seq data suggest that
SHP-2 and PD-L1 protein are co-expressed in LUAD tumor tissue and that activation of SHP-
2, not simply expression, may control levels of PD-L1. However, without knowing the expres-
sion levels of inactive SHP-2, we cannot state with certainty that SHP-2 activity is the primary
role by which SHP-2 regulates PD-L1 expression.
PTPN11 mRNA expression weakly associates with reduced CD274 mRNA
expression in melanoma tumors regardless of ICI exposure
Having established a connection between tumoral SHP-2 activity and PD-L1 expression, but
not corresponding gene expression levels, in lung adenocarcinomas, we sought to understand
whether PTPN11 and CD274 expression levels associate with response of patient tumors
treated with ICIs. A study was identified that analyzed single-cell RNA-sequencing (scRNA-
seq) data from 31 melanoma tumors that were either not treated with ICIs or became resistant
to ICIs following treatment. Importantly, the authors of the study were interested in character-
istics of the melanoma cells that lead to immune evasion [13]. We used the R-studio Biocon-
ductor GEOquery package to download the raw scRNA-seq transcript-per-million (TPM)
values, cell counts, and annotations from this study (GSE115978). TPM values were calculated
as described in Jerby-Arnon L., et al. [13]. We sought to answer two main questions using
these data: 1) does PTPN11 mRNA expression correlate with CD274 mRNA levels and 2) does
Fig 2. Workflow scheme for evaluation of SHP2 and PD-L1 relationships. Reverse-phase protein array (RPPA) was collected from the TCPA data
repository (https://gdc.cancer.gov/about-data/publications/pancanatlas) for 362 total patients labeled as the TCPA-LUAD-L4 data set. RNAseq data was
collected from GDC for the full TCGA-LUAD dataset (n = 585). These data were parsed to include only patients for which there was matching RPPA
data on TCPA (n = 362). Single-cell RNAseq reads for 31 melanoma tumors were collected and separated into two groups based on ICI treatment
status. Only single-cell reads for ‘malignant melanoma cells’ were retained for analysis. Tumors which had� 30 unique malignant cells with non-zero
PTPN11 values were included in the analysis. NSCLC tumors (n = 21) with sequence data were first separated into two groups based on response to ICI
treatment. Average TPM values were calculated for PTPN11 and CD274, and tumors that had PTPN11 TPM value>2 standard deviations from the
mean were excluded from the analysis.
https://doi.org/10.1371/journal.pone.0256416.g002
PLOS ONE Tumor genomic data informs benchtop experimental design
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PTPN11 expression correlate with poor response to PD-1 inhibition? The scheme for the anal-
ysis workflow is found in Fig 2B.
To address the first question, we identified the tumors which were not treated with ICI
(n = 15). For each of these samples, we established that scRNA-seq reads were available for sev-
eral cell types, including immune cell types and malignant cells. Cell types were detected by
fluorescence activated cell sorting using cell-type specific proteins. Because we are only inter-
ested in associations between PTPN11 and CD274 in tumor cells, we selected only single cells
determined to be malignant melanoma cells. Of the 15 untreated tumors, the analysis was nar-
rowed to include patient tumors that have at least 30 unique malignant cells (n = 6) resulting
in an average of 108 (range, 91–487) single-cells per tumor. To understand the proportion of
single cells in an individual tumor that expressed PTPN11, the percentage of cells with non-
zero TPM scores for PTPN11 for each tumor was calculated (Table 1).
This processing uncovered that six untreated tumors (Mel71, Mel79, Mel103, Mel80,
Mel81, Mel89) demonstrated�50% of single malignant cells (mean = 69%; range, 50–83%)
expressed PTPN11. The TPM values for PTPN11 and CD274 for all single malignant cells in
these six tumors were then assessed together, resulting in mean/standard deviation TPM val-
ues for PTPN11(1.40, 0.22) and CD274 (0.11, 0.06). We observed a similar trend similar to
that of the TCPA/NCI-GDC analysis above that elevated expression of PTPN11 associated
with lower expression of CD274 in treatment naïve tumors.
Finally for this dataset, we wanted to understand the relationship of PTPN11 and CD274
expression and response to therapy. We used the patient tumors which acquired resistance to
ICI therapy (n = 15) to ask whether the relative levels of PTPN11 and CD274 levels were differ-
ent than the treatment-naïve tumors. Again, the data were processed to include only tumors
Table 1. A. PTPN11 mRNA expression weakly associated with reduced CD274 mRNA expression in melanoma tumors regardless of ICI exposure. B. PTPN11 mRNA
expression weakly associated with reduced CD274 mRNA expression in melanoma tumors regardless of ICI exposure.
A










None Mel80 80.4 1.35 0.07 1.40 0.14
None Mel81 81.7 1.57 0.02
None Mel89 83.0 1.78 0.18
None Mel71 56.5 1.24 0.07
None Mel79 58.8 1.40 0.18
None Mel103 50.4 1.08 0.12
B










Ipilimumab+nivolumab Mel78 75.8 1.49 0.15 1.29 0.09
Ipilimumab+pembrolizumab Mel110 82.1 1.39 0.05
Tremlimumab Mel88 66.9 1.16 0.17
Ipilimumab Mel98 61.8 1.19 0.14
Ipilimumab+nivolumab Mel102 56.8 1.20 0.03
Ipilimumab+pembrolizumab
+nivolumab
Mel194 59.4 1.29 0.03
A. Six tumors had� 30 unique malignant cells that had non-zero PTPN11 TPM values and are ICI therapy naïve [13]. Shown are the percentage of single cells that
expressed PTPN11, the combined TPM values for all the single cells within each individual tumor, and the average TPM values for all six untreated tumors combined. B.
The same details as (A) but for tumors that did not respond to ICI therapy. There was no significant difference in average PTPN11 and CD274 TPM values between
treatment naïve and treatment resistant groups.
https://doi.org/10.1371/journal.pone.0256416.t001
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with� 30 unique malignant cells (n = 6) resulting in an average of 79 single cells (range, 96–
169) per tumor. We applied the methods used above to calculate the proportion of single cells
expressing PTPN11 for each tumor, and the average TPM values for PTPN11 and CD274
when the single cells of all six tumors were evaluated together. We found that these six ICI
resistant tumors (Mel78, Mel88, Mel98, Mel102, 196 Mel110, Mel94) again showed�50% sin-
gle malignant cells (mean = 67%; range, 57–82%) expressed PTPN11, and the combined
mean/standard deviation TPM values for PTPN11 (1.29, 0.12) and CD274 (0.09, 0.06). Here,
similar expression patterns of PTPN11 and CD274 were observed compared with treatment-
naive tumors, and again CD274 levels remain low when PTPN11 is expressed. Importantly, we
were unable to observe any relationship between PTPN11 or CD274 expression and acquired
resistance to ICI in this dataset.
CD274, but not PTPN11, mRNA expression associated with response to
ICI in NSCLC tumors
Using the data from the third study, we asked whether expression of PTPN11 and CD274
mRNA associates with response to ICI therapy in NSCLC. The investigators in this report
aimed to find immune signatures predictive of response to anti- PD-1 inhibitors in NSCLC.
The dataset contained bulk tumor RNA-sequencing data and clinical response data for 21
NSCLC subjects treated with single agent anti-PD-1 therapy [14]. As before, the R-studio Bio-
conductor GEOquery package was used to capture raw RNA-sequencing TPM values from
this study (GSE136961). Patients demonstrating progression of disease or stable disease that
lasted less than 24 weeks were deemed by the authors to have no durable clinical benefit
(DCB) to anti-PD-1 therapy. Patients showing partial or complete response by Response Eval-
uation Criteria in Solid Tumor (RECIST) v1.1 or stable disease for more than 24 weeks were
defined as receiving DCB. The analysis of these data followed a workflow scheme like that in
Fig 2C.
Of the 21 NSCLC patients in this study, nine demonstrated a DCB to ICI therapy and
twelve showed no DCB. We separated the data by DCB status and then averaged all TPM val-
ues for PTPN11 and CD274 for each patient tumor to generate one average TPM score for
each group. An outlier analysis was performed on the PTPN11 TPM values for both respond-
ers and non-responders (S3 Fig), resulting in final groups of 7 responders (n = 7) and 11 non-
responders (n = 11). Our analysis revealed no significant difference in the expression of
PTPN11 mRNA between subjects with DCB from those that did not respond to anti-PD-1
therapy (Fig 3). Specifically, the mean/standard deviation PTPN11 TPM scores were (576.15,
281.78) and (487.73, 361.24) for responders and non-responders, respectively. Importantly,
the mean expression of CD274 mRNA was nearly 3-fold higher in patients who responded to
therapy (151.16, 198.33) compared to those who did not (61.96, 64.54). We note the standard
deviation was large for the last two groups assessed. Together, these data showed that PTPN11
expression does not associate with CD274 expression or response therapy in NSCLC patients.
These findings are consistent with the results from the first study that suggested that SHP-2
activity, not expression, correlates with PD-L1 expression. In contrast, these data demon-
strated a positive relationship between PD-L1 expression and response to ICI which was not
observed in the melanoma study.
Discussion
In this study, we applied information obtained from publicly-available protein and gene
expression datasets to gain further insight into our overarching research question: does SHP-2
activity or expression influence PD-L1 mRNA and protein levels and subsequent response to
PLOS ONE Tumor genomic data informs benchtop experimental design
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Fig 3. CD274, but not PTPN11, mRNA expression is associated with response to ICI in NSCLC tumors. A.
PTPN11 TPM values for patients who did or did not demonstrate a durable clinical benefit (DCB) from ICI therapy, as
determined by RECIST criteria [14]. There was no significant difference between groups, as measured by a student’s t-
test. B. TPM values for CD274 in patients who did or did not demonstrate a durable clinical benefit (DCB) from ICI
therapy, as determined by RECIST criteria. There was no significant difference between groups, as measured by a
student’s t-test.
https://doi.org/10.1371/journal.pone.0256416.g003
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anti-PD-1 or PD-L1 therapies in NSCLC? We used this approach because we believe that the
utilization of real-world datasets can inform and direct wet-lab experimentation. The design
and execution of pre-clinical and clinical studies is expensive, time-consuming, and labor-
intensive. Here, we present a quick and efficient process that, when combined with bench-side
techniques, can offer substantial insight into the clinical translatability of commonly-used,
highly-controlled model systems designed for drug discovery applications. Through the analy-
sis of two major cancer data repositories and two smaller clinical studies, we were able to take
further steps towards establishing a connection between the activity of SHP-2 and PD-L1
expression in human tumors without carrying out a study de novo.
Of the datasets chosen for this study, the most statistically-powerful and revealing informa-
tion arose from the composite analyses of the TCPA and GDC data repositories. Using geno-
mic and protein information from a large cohort of NSCLC patients, our most important
observation was the strong negative correlation (r = -0.157, p-value = 0.0028��) between the
active, tyrosyl-phosphorylated form of SHP-2 and PD-L1 protein expression (Fig 1A). A limi-
tation of these data was that the RPPA data did not include expression levels of the unpho-
sphorylated and inactive form of SHP-2 which would have been a useful control as informed
by our wet-lab studies. However, to address this limitation, we investigated the relationship of
SHP-2 at Y542 with known targets. We found strong positive correlations in the expression
levels of SHP2_pY542 and three proteins (Src, MAPK, STAT3) whose activity is dependent on
phosphorylation status and known to be regulated by SHP-2 activity [16–18]. While this is not
a perfect control to confirm that the activity of SHP-2 predominates total SHP-2 expression as
they relate to PD-L1 expression, it does provide additional evidence that quantifies association
of SHP2_pY542 with known substrates.
The conformational changes induced by phosphorylation of SHP-2 could alter protein-pro-
tein interactions among signaling components and intracellular signaling cascades that impact
PD-L1 expression [19]. Following from that hypothesis, we observed no statistically significant
correlation between the levels of SHP-2 and PD-L1 mRNA in the patients in the NCI-GDC
dataset that were initially studied in the TCPA dataset, again highlighting the potential impor-
tance of molecular interactions of SHP-2 dependent on its activated state. Interestingly, when
we conducted the same analysis on the entire cohort of LUAD patients in the NCI-GDC repos-
itory, a weak, but inverse correlation, (r = 0.095, p-value = 0.0211�) between PTPN11 and
CD274 mRNA was observed, suggesting that SHP-2 and PD-L1 are co-expressed in LUAD
tumors. It is then plausible that SHP-2 activation may function to finetune PD-L1 expression
levels. In immune cells, SHP-2 functions downstream of the PD-1:PD-L1 interaction by facili-
tating the internalization of the PD-1 receptor which ultimately results in the deactivation of
the immune cell [20]. Likewise, it is conceivable that SHP-2 functions in a similar manner with
regard to tumoral PD-L1 expression. The significance of SHP-2 co-expression with PD-L1
mRNA may be in a negative feedback loop, reducing PD-L1 levels once its expression is no
longer necessary. Mutation of SHP-2 in malignant cells may alter SHP-2 activity or expression
to disrupt this negative feedback loop, resulting in the aberrant constitutive expression of
PD-L1 protein and continuous T-cell deactivation.
When we embarked on our studies, we most desired to understand how SHP-2 influences
response to ICI therapy in KRAS-active tumors in order to direct our drug discovery efforts in
a wet-lab setting. A limitation of the data deposited in the NCI-GDC is that the clinical data
are often incomplete and lacking details on drug treatment and associated response or perhaps
pre-date a particular therapy, like ICI in this case. However, we were able to address the
expression of SHP-2 and PD-L1 in KRAS-active LUAD (~26% of the tumors). KRAS status
did not change the outcome of the analysis. We identified other studies in which RNAseq data
was collected from tumors treated with ICIs, one in melanoma and one in NSCLC [13, 14].
PLOS ONE Tumor genomic data informs benchtop experimental design
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While the focus of our study is on NSCLC, treatment of melanoma using ICIs was approved a
few years prior to use in NSCLC, and thus the data available in this cancer with respect to ICI
treatment is more mature. It should be noted that melanomas rarely harbor KRAS mutations
and more often HRAS mutations. Neither of the two small studies made the mutation status of
Ras available.
The melanoma study was embarked by Regev and colleagues [13] and sought identify a
gene expression profile that is associated with immune evasion that might predict response to
ICI treatment. They conducted scRNAseq on melanoma tumors that were either untreated at
the time of sequencing, or had acquired resistance to ICI therapy. These data allowed us to
determine whether PTPN11 and CD274 gene expression associated with response to therapy.
The authors of the study were more interested with defining signatures of resistance that could
be used to screen patients prior to ICI therapy, so the experimental design was not ideal and
the sample size was small. Importantly, PTPN11 mRNA levels were roughly equivalent
between the treatment naïve and ICI resistant tumors. While this analysis provides some
insight into the landscape of SHP-2 and PD-L1 coexpression, it is important to acknowledge
that these tumors did not originate from the lung, have differing oncogenic mutations, and
sample sizes were relatively low.
Finally, we used data from the NSCLC study carried out by Hwang and colleagues in which
they sought to identify immune gene signatures that may predict clinical response to anti-PD-
1 therapy [14]. The authors performed RNAseq on 21 NSCLC tumors that were divided by
response to ICI therapy. For our analysis, we used average TPM values for PTPN11 and
CD274 and compared tumors based on response to therapy. Expression of PTPN11 did not
associate with DCB, but the tumors from patients who experienced DCB displayed increased
expression of CD274 mRNA, consistent with other studies [21–23]. Taken together, these two
studies do not suggest that the expression of PTPN11 mRNA is associated with to response to
ICI therapy. Given these analyses considered alongside the TCPA analysis, it is likely that
SHP-2 activity, not expression, bears more importance to PD-L1 expression, and subsequently
response to ICI therapy, in NSCLC. Further, our findings suggest that reducing SHP-2 activity
by pharmacological means would increase tumoral PD-L1 expression. Patients with PD-L1
expression >50% respond better to ICI therapy, supporting the potential for synergy of the co-
inhibition of SHP-2 and PD-L1 in NSCLC [23–25].
This study outlines the significance of using of simple and efficient methods in real-world
data analysis to further discovery efforts at the benchtop. Each study from which we gathered
data had limitations that we have noted. The take-home message is that there is likely value in
combining the use of molecules that inhibit the activity of SHP-2 and ICI in lung tumors and
convince us that continued exploration into the role of SHP-2 on both PD-L1 expression is
clinically important.
Supporting information
S1 Fig. SHP2_pY542 significantly correlates with phosphorylated proteins found in path-
ways that are SHP-2 targets. A. Two-tailed non-parametric Spearman correlation analysis of
RPPA protein expression data for Y542 phosphorylated SHP-2 and T202/Y204 phosphory-
lated MAPK B. Y527 phosphorylated Src kinase C. Y416 phosphorylated Src kinase D. Y705
phosphorylated STAT3 from 362 adenocarcinomas taken from The Cancer Proteome Atlas
(TCPA: https://gdc.cancer.gov/about-data/publications/pancanatlas) LUAD-L4 dataset. The
red line represents a linear regression line of best fit.
(TIF)
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S2 Fig. KRAS mutation status had no impact on PTPN11 and CD274 relationship. Two-
tailed non-parametric Spearman correlation analysis of bulk RNA-seq FPKM-UQ values
taken from TCGA (GDC: https://gdc.cancer.gov/about-data/publications/pancanatlas) for 99
patients harboring mutations in the KRAS gene found in the TCGA-LUAD dataset. The red
line represents a linear regression line of best fit.
(TIF)
S3 Fig. Outlier analysis of PTPN11 TPM values for NSCLC response study. Box and whis-
ker plot of PTPN11 TPM values for NSCLC patients who did not respond to ICI therapy (A)
or patients who did respond (B). Outliers, highlighted in red, were determined by the 1.5 inter-
quartile range (IQR) method which adds 1.5 times the IQR to the third quartile and excludes
data points that fall above that value, and subtracts 1.5 times the IQR from the first quartile
and excludes data points that fall below that value.
(TIF)
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